Optimal Lipid Modification: The Rationale for Combination Therapy

References

• AldridgeMAItoMKColesevelam hydrochloride: A novel bile acid-binding resinAnn Pharmacother20013589890711485143
   PubMed Web of Science ®Google Scholar
• AltschulRHofferAStephenJDInfluence of nicotinic acid on serum cholesterol in manArch Biochem Biophys1955545589
   PubMed Web of Science ®Google Scholar
• [AHA] American Heart AssociationHeart disease and stroke statistics – 2005 update2005Dallas, Texas, USAHA
   Google Scholar
• AndradeSEWalkerAMGottliebLKDiscontinuation of antihyperlipidemic drugs – Do rates reported in clinical trials reflect rates in primary care settings?N Engl J Med19953321125317700285
   PubMed Web of Science ®Google Scholar
• AnonymousClofibrate and niacin in coronary heart diseaseJAMA1975231360811088963
   PubMed Web of Science ®Google Scholar
• AnonymousThe Lipid Research Clinics Coronary Primary Prevention Trial results. Reduction in incidence of coronary heart diseaseJAMA1984251351646361299
   PubMed Web of Science ®Google Scholar
• AnonymousRandomised trial of cholesterol lowering in 4444 patients with coronary heart disease: the Scandinavian Simvastatin Survival Study (4S)Lancet1994344138397968073
   PubMed Web of Science ®Google Scholar
• AradYRamakrishnanRGinsbergHNEffects of lovastatin therapy on very-low-density lipoprotein triglyceride metabolism in subjects with combined hyperlipidemia: evidence for reduced assembly and secretion of triglyceride-rich lipoproteinsMetabolism199241487931588827
   PubMed Web of Science ®Google Scholar
• AsbergAHartmannAFjeldsåEAtorvastatin improves endothelial function in renal-transplant recipientsNephrol Dial Transplant2001161920411522880
   PubMed Web of Science ®Google Scholar
• AthyrosVGDemitriadisDSPapageorgiouAAAtorvastatin and micronized fenofibrate alone and in combination in type 2 diabetes with combined hyperlipidemiaDiabetes Care200225119820212087019
   PubMed Web of Science ®Google Scholar
• AthyrosVGPapageorgiouAAHatzikonstandinouHSafety and efficacy of long-term statin-fibrate combinations in patients with refractory combined hyperlipidemiaAm J Cardiol199780608139294990
   PubMed Web of Science ®Google Scholar
• [ATP-III] Expert Panel on Detection, Evaluation and Treatment of High Blood Cholesterol in Adults - Adult Treatment Panel III (ATP-III)Third report of the National Cholesterol Education Program (NCEP) expert panel on detection, evaluation, and treatment of high blood cholesterol in adultsCirculation2002106314342112485966
   PubMed Web of Science ®Google Scholar
• BackesJHowardPMoriartyPRole of C-reactive protein in cardiovascular diseaseAnn Pharmacother2004381101814742804
   PubMed Web of Science ®Google Scholar
• BackesJGibsonCAEffect of lipid-lowering drug therapy on small-dense low-density lipoproteinAnn Pharmacother200539523615671087
   PubMed Web of Science ®Google Scholar
• BackmanJTKyrklundCKivistoKTPlasma concentrations of active simvastatin acid are increased by gemfibrozilClin Pharmacol Ther200068122910976543
   PubMed Web of Science ®Google Scholar
• BackmanJTKyrklundCNeuvonenMGemfibrozil greatly increases plasma concentrations of cerivastatinClin Pharmacol Ther2002726859112496749
   PubMed Web of Science ®Google Scholar
• BallantyneCMCorsiniADavidsonMHRisk for myopathy with statin therapy in high-risk patientsArch Intern Med20031635536412622602
   PubMed Web of Science ®Google Scholar
• BallantyneCMHouriJNotarbartoloAEffect of ezetimibe coadministered with atorvastatin in 628 patients with primary hypercholesterolemiaCirculation200310724091512719279
   PubMed Web of Science ®Google Scholar
• BallantyneCMAbateNYuanZDose-comparison study of the combination of ezetimibe and simvastatin (Vytorin) versus atorvastatin in patients with hypercholesterolemia: The Vytorin Versus Atorvastatin (VYVA) StudyAm Heart J20051494647315864235
   PubMed Web of Science ®Google Scholar
• BauerKSKosoglouTStatkevichPEzetimibe does not affect the pharmacokinetics or pharmacodynamics of warfarin [abstract]Clin Pharmacol Ther2001695
   Web of Science ®Google Scholar
• BaysHEDujovneCAMcGovernMEComparison of once-daily, niacin extended-release/lovastatin with standard doses of atorvastatin and simvastatin (the ADvicor Versus Other Cholesterol-Modulating Agents Trial Evaluation [ADVOCATE])Am J Cardiol2003916677212633795
   PubMed Web of Science ®Google Scholar
• BaysHEMoorePBDrehobiMAEzetimibe Study Group. Effectiveness and tolerability of ezetimibe in patients with primary hypercholesterolemia: pooled analysis of two phase II studiesClin Ther20012312093011558859
   PubMed Web of Science ®Google Scholar
• BaysHEOseLFraserNA multicenter, randomized, double-blind, placebo-controlled, factorial design study to evaluate the lipid-altering efficacy and safety profile of the ezetimibe/simvastatin tablet compared with ezetimibe and simvastatin monotherapy in patients with primary hypercholeserolemiaClin Ther20042617587315639688
   PubMed Web of Science ®Google Scholar
• BellDSOvalleFOutcomes of initiation of therapy with once-daily combination of a thiazolidinedione and a biguanide at an early stage of type 2 diabetesDiabetes Obes Metab20046363615287929
   PubMed Web of Science ®Google Scholar
• BergeKGSide effects of nicotinic acid in treatment of hypercholesteremiaGeriatrics19611641622
   Web of Science ®Google Scholar
• BergmanAJMurphyGBurkeJSimvastatin does not have a clinically significant pharmacokinetic interaction with fenofibrate in humansJ Clin Pharmacol20044410546215317833
   PubMed Web of Science ®Google Scholar
• BilheimerDWGrundySMBrownMSMevinolin and colestipol stimulate receptor-mediated clearance of low-density lipoprotein from plasma in familial hypercholesterolemia heterozygotesProc Natl Acad Sci U S A198380412486575399
   PubMed Web of Science ®Google Scholar
• BlaneGFBogaievskyYBonnefousFFearsRFenofibrate: influence on circulating lipids and side effects in medium and long-term clinical usePharmacological control of hyperlipidemia1986BarcelonaJR Prous Sci Pub187216
   Google Scholar
• BlumlBMMcKenneyJMCzirakyMJPharmaceutical care services and results in project ImPACT: hyperlipidemiaJ Am Pharm Assoc20004015765
   Google Scholar
• BradfordRHShearCLChremosANExpanded Clinical Evaluation of Lovastatin (EXCEL) study results. Efficacy in modifying plasma lipoproteins and adverse event profile in 8245 patients with moderate hypercholesterolemiaArch Intern Med19911514391985608
   PubMed Web of Science ®Google Scholar
• BrownWVFenofibrate, a third-generation fibric acid derivativeAm Heart J198783Suppl 5B12
   Google Scholar
• BrownGAlbersJJFisherLDRegression of coronary artery disease as a result of intensive lipid-lowering therapy in men with high levels of apolipoproteinN Engl J Med19903231289982215615
   PubMed Web of Science ®Google Scholar
• BrownBGBardsleyJPoulinDModerate dose, three-drug therapy with niacin, lovastatin, and colestipol to reduce low-density lipoprotein cholesterol <100 mg/dl in patients with hyperlipidemia and coronary artery diseaseAm J Cardiol199780111159230143
   PubMed Web of Science ®Google Scholar
• BrownBGZambonAPoulinDUse of niacin, statins and resins in patients with combined hyperlipidemiaAm J Cardiol199881Suppl 4A52B59B
   PubMed Web of Science ®Google Scholar
• BrownBGZhaoXQChaitASimvastatin and niacin, antioxidant vitamins, or the combination for the prevention of coronary diseaseN Engl J Med200134515839211757504
   PubMed Web of Science ®Google Scholar
• BrownWVNovel approaches to lipid lowering: what is on the horizon?Am J Cardiol200187Suppl23B27B
   PubMedGoogle Scholar
• CannonCPBraunwaldEMcCabeCHPravastatin or Atorvastatin Evaluation and Infection Therapy-Thrombolysis in Myocardial Infarction 22 (PROVE IT-TIMI 22) Investigators. Intensive versus moderate lipid lowering with statins after acute coronary syndromesN Engl J Med2004350149550415007110
   PubMed Web of Science ®Google Scholar
• ChapmanRHBennerJSPetrillaAAPredictors of adherence with antihypertensive and lipid-lowering therapyArch Intern Med200516511475215911728
   PubMed Web of Science ®Google Scholar
• ChobanianAVBakrisGLBlackHRNational Heart, Lung, and Blood Institute Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure; National High Blood Pressure Education Program Coordinating Committee. The Seventh Report of the Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure: the JNC 7 reportJAMA200328925607212748199
   PubMed Web of Science ®Google Scholar
• ChungNChoSYChoiDHSTATT: a titrate-to-goal study of simvastatin in Asian patients with coronary heart disease. Simvastatin Treats Asians to TargetClin Ther2001238587011440286
   PubMed Web of Science ®Google Scholar
• [CPI] The Committee of Principal InvestigatorsA co-operative trial in the primary prevention of ischaemic heart disease using clofibrateBr Heart J1978401069118361054
   PubMedGoogle Scholar
• CoteMCLigetiRCutlerBSManagement of hyperlipidemia in patients with vascular diseaseJ Vasc Nurs20032163712813414
   PubMedGoogle Scholar
• [DAIS] DAIS-InvestigatorsEffect of fenofibrate on progression of coronary-artery disease in type 2 diabetes: the Diabetes Atherosclerosis Intervention Study, a randomised studyLancet20013579051011289345
   PubMed Web of Science ®Google Scholar
• DavignonJMontignyMDufourRHMG-CoA reductase inhibitors: a look back and a look aheadCan J Cardiol19928843641423005
   PubMed Web of Science ®Google Scholar
• DavidsonMHCombination therapy for dyslipidemia: safety and regulatory considerationsAm J Cardiol200290Suppl50K60K
   PubMedGoogle Scholar
• DavidsonMHTothPPCombination therapy in the management of complex dyslipidemiasCurr Opin Lipidol2004154233115243215
   PubMed Web of Science ®Google Scholar
• DavidsonMHMakiKCPearsonTAResults of the National Cholesterol Education (NCEP) Program Evaluation Project Utilizing Novel E-Technology (NEPTUNE) II survey and implications for treatment under the recent NCEP Writing Group recommendationsAm J Cardiol2005965566316098311
   PubMed Web of Science ®Google Scholar
• DeBuskRFMillerNHSuperkoHRA case-management system for coronary risk factor modification after acute myocardial infarctionAnn Intern Med199412072198147544
   PubMed Web of Science ®Google Scholar
• DerosaGCiceroAFBertoneGComparison of fluvastatin + fenofibrate combination therapy and fluvastatin monotherapy in the treatment of combined hyperlipidemia, type 2 diabetes mellitus, and coronary heart disease: A 12-month, randomized, double-blind, controlled trialClin Ther200426159960715598476
   PubMed Web of Science ®Google Scholar
• ElamMBHunninghakeDBDavisKBEffect of niacin on lipid and lipoprotein levels and glycemic control in patients with diabetes and peripheral arterial disease: the ADMIT study: a randomized trialJAMA200028412637010979113
   PubMed Web of Science ®Google Scholar
• FaulknerMAWadibiaECLucasBDImpact of pharmacy counseling on compliance and effectiveness of combination lipid-lowering therapy in patients undergoing coronary artery revascularization: a randomized, controlled trialPharmacotherapy2000204101610772372
   PubMed Web of Science ®Google Scholar
• FonarowGCFrenchWJParsonsLSUse of lipid-lowering medications at discharge in patients with acute myocardial infarction: data from the National Registry of Myocardial Infarction 3Circulation2001103384411136683
   PubMed Web of Science ®Google Scholar
• FrickMHEloOHaapaKHelsinki Heart Study: primaryprevention trial with gemfibrozil in middle-aged men with dyslipidemia: safety of treatment, changes in risk factors, and incidence of coronary heart diseaseN Engl J Med19873171237453313041
   PubMed Web of Science ®Google Scholar
• FruchartJCBrewerHBLeitersdorfEConsensus for the use of fibrates in the treatment of dyslipoproteinemia and coronary heart diseaseAm J Cardiol199881912179555782
   PubMed Web of Science ®Google Scholar
• FurbergCDLipid-lowering trials: results and limitationsAm Heart J1994128130487977011
   PubMed Web of Science ®Google Scholar
• FuxRMorikeKGrundelUFEzetimibe and statin-associated myopathyAnn Intern Med2004140671215096354
   PubMed Web of Science ®Google Scholar
• GagneCBaysHEWeissSREfficacy and safety of ezetimibe added to ongoing statin therapy for treatment of patients with primary hypercholesterolemiaAm J Cardiol20029010849112423708
   PubMed Web of Science ®Google Scholar
• GawAPackardCJLindsayGMEffects of colestipol alone and in combination with simvastatin on apolipoprotein B metabolismArterioscler Thromb Vasc Biol199616236498620338
   PubMed Web of Science ®Google Scholar
• GordonDJProbstfieldJLGarrisonRJHigh-density lipoprotein cholesterol and cardiovascular disease: four prospective American studiesCirculation1989798152642759
   PubMed Web of Science ®Google Scholar
• GrahamDJStaffaJAShatinDIncidence of hospitalized rhabdomyolysis in patients treated with lipid-lowering drugsJAMA200429225859015572716
   PubMed Web of Science ®Google Scholar
• GriffinBAFreemanDJTaitGWRole of plasma triglycerides in the regulation of plasma low density lipoprotein (LDL-C) subfractions: relative contribution of small, dense LDL-C to coronary heart disease riskAtherosclerosis1994106241538060384
   PubMed Web of Science ®Google Scholar
• GrundySMAhrensEHSalenGInterruption of the enterohepatic circulation of bile acids in man: comparative effects of cholestyramine and ileal exclusion on cholesterol metabolismJ Lab Clin Med1971178941215569253
   PubMedGoogle Scholar
• GrundySMMokHYIZechLInfluence of nicotinic acid on metabolism of cholesterol and triglycerides in manJ Lipid Res19812224367217784
   PubMed Web of Science ®Google Scholar
• GrundySMVegaGLFibric acids: effects of lipids and lipoprotein metabolismAm J Med198786Suppl 5B9203318457
   PubMedGoogle Scholar
• GrundySMCleemanJIMerzCNCoordinating committee of the national cholesterol education program. Implications of recent clinical trials for the National Cholesterol Education Program Adult Treatment Panel III GuidelinesJ Am Coll Cardiol2004447203215358046
   PubMed Web of Science ®Google Scholar
• GuptaEKItoMKLovastatin and extended-release niacin combination product: the first drug combination for the management of hyperlipidemiaHeart Dis200241243711975844
   PubMedGoogle Scholar
• GuytonJRGoldbergACKreisbergRAEffectiveness of oncenightly dosing of extended-release niacin alone and in combination for hypercholesterolemiaAm J Cardiol199882737439761083
   PubMed Web of Science ®Google Scholar
• HaskellWLAldermanELFairJMEffects of intensive multiple risk factor reduction on coronary atherosclerosis and clinical cardiac events in men and women with coronary artery disease. The Stanford Coronary Risk Intervention Project (SCRIP)Circulation199489975908124838
   PubMed Web of Science ®Google Scholar
• [HPSCG] Heart Protection Study Collaborative GroupMRC/BHF Heart Protection Study of cholesterol lowering with simvastatin in 20536 high-risk individuals: a randomised placebo-controlled trialLancet200236072212114036
   PubMed Web of Science ®Google Scholar
• HolmeIEffects of lipid-lowering therapy on total and coronary mortalityCurr Opin Lipidol1995637488750251
   PubMed Web of Science ®Google Scholar
• HorneRWeinmanJPatients' beliefs about prescribed medicines and their role in adherence to treatment in chronic physical illnessJ Psych Res19994755567
   Google Scholar
• HottelartCEl EsperNRoseFFenofibrate increases creatininemia by increasing metabolic production of creatinineNephron2002925364112372935
   PubMed Web of Science ®Google Scholar
• HsuISpinlerSAJohnsonNEComparative evaluation of the safety and efficacy of HMG-CoA reductase inhibitor monotherapy in the treatment of primary hypercholesterolemiaAnn Pharmacother199529743598520093
   PubMed Web of Science ®Google Scholar
• InsullWThe problem of compliance to cholesterol altering therapyJ Intern Med1997241317259159603
   PubMed Web of Science ®Google Scholar
• IsaacsohnJLLaSalleJChaoGComparison of treatment with fluvastatin extended-release 80-mg tablets and immediate-release 40-mg capsules in patients with primary hypercholesterolemiaClin Ther2003259041812852707
   PubMed Web of Science ®Google Scholar
• JonesPHDavidsonMHSteinEAComparison of the Efficacy and Safety of Rosuvastatin Versus Atorvastatin, Simvastatin, and Pravastatin Across Doses (STELLAR Trial)Am J Cardiol2003931526012860216
   PubMed Web of Science ®Google Scholar
• JonesPHDavidsonMHReporting rate of rhabdomyolysis with fenofibrate + statin versus gemfibrozil + any statinAm J Cardiol2005951202215619408
   PubMed Web of Science ®Google Scholar
• KaplanRCBhalodkarNCBrownEJJrRace, ethnicity, and sociocultural characteristics predict noncompliance with lipid-lowering medicationsPrev Med20043912495515539064
   PubMed Web of Science ®Google Scholar
• KashyapMLEvansRSimmonsPJNew combination niacin/statin formulation shows pronounced effects on major lipoproteins and is well tolerated [abstract]J Am Coll Cardiol200035Suppl A326A
   Google Scholar
• KashyapMLMcGovernMEBerraKLong-term safety and efficacy of a once-daily niacin/lovastatin formulation for patients with dyslipidemiaAm J Cardiol2002896727811897208
   PubMed Web of Science ®Google Scholar
• KeungACFKosoglouTStatkevichPEzetimibe does not affect the pharmacokinetics of oral contraceptives [abstract]Clin Pharmacol Ther20016955
   Web of Science ®Google Scholar
• KnappHHSchrottHMaPEfficacy and safety of combination simvastatin and colesevelam in patients with primary hypercholesterolemiaAm J Med20011103526011286949
   PubMed Web of Science ®Google Scholar
• KnoppRHGinsbergJAlbersJJContrasting effects of unmodified and time-release forms of niacin on lipoproteins in hyperlipidemic subjects: clues to mechanism of action of niacinMetabolism198534642503925290
   PubMed Web of Science ®Google Scholar
• KnoppRHBrownWVDujovneCAEffects of fenofibrate on plasma lipoproteins in hypercholesterolemia and combined hyperlipidemiaAm J Med1987835093318454
   PubMed Web of Science ®Google Scholar
• KonzemSLGrayDRKashyapMLEffect of pharmaceutical care on optimum colestipol treatment in elderly hypercholesterolemic veteransPharmacotherapy199717576839165562
   PubMed Web of Science ®Google Scholar
• KosoglouTGuillaumeMSunSPharmacodynamic interaction between fenofibrate and the cholesterol absorption inhibitor ezetimibe [abstract]Atherosclerosis20012Suppl38
   Google Scholar
• KosoglouTMeyerIMusiolBPharmacodynamic interaction between fluvastatin and ezetimibe has favorable clinical implications [abstract]Atherosclerosis20012Suppl89 2001
   Google Scholar
• KyrklundCBackmanJTKivistöKTPlasma concentrations of active lovastatin acid are markedly increased by gemfibrozil but not by bezafibrateClin Pharmacol Ther200169340511372002
   PubMed Web of Science ®Google Scholar
• LamarcheBTchernofAMoorjaniSSmall, dense low-density lipoprotein particles as a predictor of the risk of ischemic heart disease in men: prospective results from the Quebec Cardiovascular StudyCirculation19979569758994419
   PubMed Web of Science ®Google Scholar
• LaRosaJHLaRosaJCEnhancing drug compliance in lipid-lowering treatmentArch Fam Med2000911697511115225
   PubMedGoogle Scholar
• LaRosaJCGrundySMWatersDDIntensive lipid lowering with atorvastatin in patients with stable coronary diseaseN Engl J Med200535214253515755765
   PubMed Web of Science ®Google Scholar
• LiamisGKakafikaABairaktariECombined treatment with fibrates and small doses of atorvastatin in patients with mixed dyslipidemiaCurr Med Res Opin200218125812094821
   PubMed Web of Science ®Google Scholar
• LuepkerRVPatient adherence: a ‘risk factor’ for cardiovascular diseaseHeart Dis Stroke19932418218137045
   PubMedGoogle Scholar
• MaenpaaHManninenVHeinonenOPCompliance with medication in the Helsinki Heart StudyEur J Clin Pharmacol19924215191541311
   PubMed Web of Science ®Google Scholar
• MalloyMJKaneJPKunitakeSTComplementarity of colestipol, niacin, and lovastatin in treatment of severe familial hypercholesterolemiaAnn Intern Med1987107616233662275
   PubMed Web of Science ®Google Scholar
• MartinPDDaneALSchneckDWAn open-label, randomized, three-way crossover trial of the effects of coadministration of rosuvastatin and fenofibrate on the pharmacokinetic properties of rosuvastatin and fenofibric acid in healthy male volunteersClin Ther2003254597112749507
   PubMed Web of Science ®Google Scholar
• MasanaLMataPGagneCLong-term safety and tolerability profiles and lipid-modifying efficacy of ezetimibe coadministered with ongoing simvastatin treatment: a multicenter, randomized, double-blind, placebo-controlled, 48-week extension studyClin Ther2005271748415811480
   PubMed Web of Science ®Google Scholar
• MatersonBJRedaDJCushmanWCSingle-drug therapy for hypertension in men: a comparison of six antihypertensive agents with placeboN Engl J Med199332891421 (Erratum, 1994 N Engl J Med, 330:1689)8446138
   PubMed Web of Science ®Google Scholar
• MavigliaSMTeichJMFiskioJUsing an electronic medical record to identify opportunities to improve compliance with cholesterol guidelinesJ Gen Intern Med200116531711556929
   PubMed Web of Science ®Google Scholar
• McKenneyJMProctorJDHarrisSA comparison of the efficacy and toxic effects of sustained- vs immediate-release niacin in hypercholesterolemic patientsJAMA199427167278309029
   PubMed Web of Science ®Google Scholar
• McKenneyJMCombination therapy for elevated low-density lipoprotein cholesterol: the key to coronary artery disease risk reductionAm J Cardiol200290Suppl8K20K
   PubMedGoogle Scholar
• McKenneyJMNew perspectives on the use of niacin in the treatment of lipid disordersArch Intern Med200416469770515078639
   PubMed Web of Science ®Google Scholar
• MelaniLMillsRHassmanDEfficacy and safety of ezetimibe coadministered with pravastatin in patients with primary hypercholesterolemia: a prospective, randomized, double-blind trialEur Heart J2003247172812713766
   PubMed Web of Science ®Google Scholar
• MiettinenTARailoMLepäntaloMPlant sterols in serum and in atherosclerotic plaques of patients undergoing carotid endarterectomyJ Am Coll Cardiol200545179480115936608
   PubMed Web of Science ®Google Scholar
• Merck/Schering-PloughManufacturer letter. Unpublished data. Available from Merck/Schering-Plough Pharmaceuticals2005North Wales, PA, USA
   Google Scholar
• MoonYSKashyapMLNiacin extended-release/lovastatin: combination therapy for lipid disordersExpert Opin Pharmacother2002317637112472373
   PubMedGoogle Scholar
• NestelPJGrundySMChanges in plasma triglyceride metabolism during withdrawal of bileMetabolism197625125968185488
   PubMed Web of Science ®Google Scholar
• NutescuEAShapiroNLEzetimibe: a selective cholesterol absorption inhibitorPharmacotherapy20032314637414620392
   PubMed Web of Science ®Google Scholar
• PanHYDeVaultARSwitesBJPharmacokinetics and pharmacodynamics of pravastatin alone and with cholestyramine in hypercholesterolemiaClin Pharmacol Ther19904820172116260
   PubMed Web of Science ®Google Scholar
• PanWJGustavsonLDAchariRLack of a clinically significant pharmacokinetic interaction between fenofibrate and pravastatin in healthy volunteersJ Clin Pharmacol2000403162310709162
   PubMed Web of Science ®Google Scholar
• PasternakRCGrundySMSmithSCACC/AHA/NHLBI Clinical Advisory on the Use and Safety of StatinsJ Am Coll Cardiol20024056873
   Web of Science ®Google Scholar
• PearsonTAThe undertreatment of LDL-cholesterol: addressing the challengeInt J Cardiol20007430
   Web of Science ®Google Scholar
• PearsonTALauroraIChuHThe Lipid Treatment Assessment Project (L-TAP): a multicenter survey to evaluate the percentages of dyslipidemic patients receiving lipid-lowering therapy and achieving low-density lipoprotein cholesterol goalsArch Intern Med20001604596710695686
   PubMed Web of Science ®Google Scholar
• PedersenTRTobertJABenefits and risks of HMG-CoA reductase inhibitors in the prevention of coronary heart disease: a reappraisalDrug Saf19961411248713485
   PubMed Web of Science ®Google Scholar
• [PMSG] Pravastatin Multicenter Study Group IIComparative efficacy and safety of pravastatin and cholestyramine alone and combined in patients with hypercholesterolemiaArch Intern Med1993153132198507122
   PubMedGoogle Scholar
• RosensonRSTangneyCCAntiatherothrombotic properties of statins: implications for cardiovascular event reductionJAMA19982791643509613915
   PubMed Web of Science ®Google Scholar
• RubinsHBRobinsSJCollinsDGemfibrozil for the secondary prevention of coronary heart disease in men with low levels of high-density lipoprotein cholesterolN Engl J Med19993414101810438259
   PubMed Web of Science ®Google Scholar
• SacksFMTonkinAMShepherdJEffect of pravastatin on coronary disease events in subgroups defined by coronary risk factors: the Prospective Pravastatin Pooling ProjectCirculation2000102189390011034935
   PubMed Web of Science ®Google Scholar
• SchusterHImproving lipid management—to titrate, combine or switchInter J Clin Prac20045868994
   PubMed Web of Science ®Google Scholar
• SchwedAFallabCLBurnierMElectronic monitoring of compliance to lipid–lowering therapy in clinical practiceJ Clin Pharm1999394029
   PubMed Web of Science ®Google Scholar
• SeverPSDahlofBPoulterNRPrevention of coronary and stroke events with atorvastatin in hypertensive patients who have average or lower-than-average cholesterol concentrations, in the Anglo-Scandinavian Cardiac Outcomes Trial—Lipid Lowering Arm (ASCOT-LLA): a multicentre randomised controlled trialLancet200336111495812686036
   PubMed Web of Science ®Google Scholar
• ShepherdJPackardCJPatschJREffects of nicotinic acid therapy on plasma high density lipoprotein subfraction distribution and composition and on apolipoprotein A metabolismJ Clin Invest19796385867221531
   PubMed Web of Science ®Google Scholar
• ShepherdJPackardCJBickerSCholestyramine promotes receptor-mediated low-density-lipoprotein catabolismN Engl J Med19803021219227366673
   PubMed Web of Science ®Google Scholar
• ShepherdJCobbeSMFordIPrevention of coronary heart disease with pravastatin in men with hypercholesterolemiaAtheroscler Suppl1995591715531281
   PubMedGoogle Scholar
• ShepherdJBlauwGJMurphyMBPravastatin in elderly individuals at risk of vascular disease (PROSPER): a randomised controlled trialLancet200236016233012457784
   PubMed Web of Science ®Google Scholar
• SiskindAJohnsonMQureshiAThe impact of automatic prescriptions on reducing low-density lipoprotein cholesterol levelsEff Clin Prac200032406
   PubMedGoogle Scholar
• SpenceJDMunozCEHendricksLPharmacokinetics of the combination of fluvastatin and gemfibrozilAm J Cardiol19957680A83A7793412
   PubMed Web of Science ®Google Scholar
• StaffaJAChangJGreenLCerivastatin and reports of fatal rhabdomyolysisN Engl J Med20023465394011844864
   PubMed Web of Science ®Google Scholar
• StatkevichPReydermanLKosoglouTEzetimibe does not affect the pharmacokinetics and pharmacodynamics of glipizide [abstract]Clin Pharmacol Ther20016867
   Google Scholar
• SteinEADavidsonMHDujovneCAEfficacy and tolerability of low-dose simvastatin and niacin, alone and in combination, in patients with combined hyperlipidemia: a prospective trialJ Cardiovasc Pharmacol Ther199611071610684407
   PubMedGoogle Scholar
• SteinEAAn investigative look: selective cholesterol absorption inhibitors-embarking on a new standard of careAm J Manag Care20028Suppl 2S36911855701
   PubMed Web of Science ®Google Scholar
• SteinerAWeisserBVetterWA comparative review of the adverse effects of treatments for hyperlipidaemiaDrug Saf19916118302043283
   PubMed Web of Science ®Google Scholar
• StrowigSMAviles-SantaMLRaskinPImproved glycemic control without weight gain using triple therapy in type 2 diabetesDiabetes Care20042715778315220231
   PubMedGoogle Scholar
• StuderMBrielMLeimenstollBEffect of different antilipidemic agents and diets on mortalityArch Intern Med20051657253015824290
   PubMed Web of Science ®Google Scholar
• TaylorAJSullenbergerLELeeHJArterial Biology for the Investigation of the Treatment Effects of Reducing Cholesterol (ARBITER) 2Circulation200411035121715537681
   PubMed Web of Science ®Google Scholar
• VakkilainenJSteinerGAnsquerJCRelationships between low-density lipoprotein particle size, plasma lipoproteins, and progression of coronary artery diseaseCirculation20031071733712665498
   PubMed Web of Science ®Google Scholar
• von BergmannKSudhopTLutjohannDCholesterol and plant sterols absorption: recent insightsAm J Cardiol20059610D14D
   PubMed Web of Science ®Google Scholar
• WattsGFMandaliaSBruntJNIndependent associations between plasma lipoprotein subfraction levels and the course of coronary artery disese in the St. Thomas' Atherosclerosis Regression Study (STARS)Metabolism199342146178231842
   PubMed Web of Science ®Google Scholar
• WildSSicreeRRoglicGGlobal prevalence of diabetes – estimates for the year 2000 and projections for 2030Diabetes Care20042710475315111519
   PubMed Web of Science ®Google Scholar
• WolfeMLVartanianSFRossJLSafety and effectiveness of Niaspan when added sequentially to a statin for treatment of dyslipidemiaAm J Cardiol200187476911179541
   PubMed Web of Science ®Google Scholar
• WorzCRBottorffMTreating dyslipidemic patients with lipid-modifying and combination therapiesPharmacotherapy2003236253712741437
   PubMed Web of Science ®Google Scholar